(Q84531531)
English
A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patient
scientific article published on 05 July 2012
Statements
A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma (English)
F Morschhauser
C Recher
P Brice
N Vey
P Colombat
J F Rossi
E Deconinck
F Lazreg
L Bergougnoux
G Delsol